^
Association details:
| Biomarker: | TP53 mutation |
|---|---|
| Cancer: | Myelodysplastic Syndrome |
| Drug: | azacitidine (DNMT inhibitor) + sabatolimab (MBG453) (TIM-3 antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study
Published date:
09/01/2021
Excerpt:
...patients with HR/vHR-MDS...and ineligible for intensive chemotherapy received sabatolimab (1–2 infusions/month) + decitabine or azacitidine....In patients with TP53 mutation or >/=1 mutation conferring European LeukemiaNet (ELN) high risk, remission rates were 55% (6/11; 4/6 in remission >200 days) and 59% (13/22; 8/13 in remission >200 days), respectively, for HR/ vHR-MDS….Sabatolimab+HMA showed favorable tolerability in MDS/AML, including in patients with grade 4 cytopenias at baseline. Promising remission rates were observed across patient subgroups.
Trial ID:
